Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations.
Felix Rafael De BieDavid BasurtoSailesh KumarJan DeprestFrancesca Maria RussoPublished in: International journal of environmental research and public health (2022)
Sildenafil, a phosphodiesterase 5 inhibitor with a vasodilatory and anti-remodeling effect, has been investigated concerning various conditions during pregnancy. Per indication, we herein review the rationale and the most relevant experimental and clinical studies, including systematic reviews and meta-analyses, when available. Indications for using sildenafil during the second and third trimester of pregnancy include maternal pulmonary hypertension, preeclampsia, preterm labor, fetal growth restriction, oligohydramnios, fetal distress, and congenital diaphragmatic hernia. For most indications, the rationale for administering prenatal sildenafil is based on limited, equivocal data from in vitro studies and rodent disease models. Clinical studies report mild maternal side effects and suggest good fetal tolerance and safety depending on the underlying pathology.
Keyphrases
- pregnancy outcomes
- pulmonary hypertension
- meta analyses
- pregnant women
- preterm birth
- pulmonary arterial hypertension
- pulmonary artery
- systematic review
- gestational age
- birth weight
- clinical trial
- low birth weight
- randomized controlled trial
- big data
- body mass index
- machine learning
- early onset
- mass spectrometry
- coronary artery